Geode Capital Management LLC Has $105.34 Million Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Geode Capital Management LLC raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,348,745 shares of the company’s stock after acquiring an additional 21,951 shares during the quarter. Geode Capital Management LLC’s holdings in Prestige Consumer Healthcare were worth $105,342,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PBH. HighTower Advisors LLC lifted its stake in Prestige Consumer Healthcare by 4.9% in the third quarter. HighTower Advisors LLC now owns 16,708 shares of the company’s stock valued at $1,215,000 after acquiring an additional 774 shares during the last quarter. Stifel Financial Corp lifted its stake in Prestige Consumer Healthcare by 13.7% in the third quarter. Stifel Financial Corp now owns 19,299 shares of the company’s stock valued at $1,391,000 after acquiring an additional 2,322 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Prestige Consumer Healthcare in the third quarter valued at about $6,342,000. Jane Street Group LLC raised its position in shares of Prestige Consumer Healthcare by 28.3% in the third quarter. Jane Street Group LLC now owns 65,373 shares of the company’s stock valued at $4,713,000 after purchasing an additional 14,434 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Prestige Consumer Healthcare in the third quarter valued at about $264,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $83.35 on Thursday. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04. The firm has a market cap of $4.13 billion, a price-to-earnings ratio of 19.52, a P/E/G ratio of 2.69 and a beta of 0.47. The firm’s 50-day simple moving average is $84.33 and its 200 day simple moving average is $79.69. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PBH shares. Canaccord Genuity Group increased their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Royal Bank of Canada increased their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research report on Friday, March 21st. StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, DA Davidson increased their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.